- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Magellan Team Discusses 'Mortgage-like' Payments For Ultra-Expensive Gene Therapies | AMCP 2023
When asked for solutions in better managing expensive drug costs, Michelle Booth of Magellan suggests a "mortgage-like" payment that could help make these therapies, which are covered under medical benefits, more accessible and affordable. Because there aren't many gene therapies out there just yet in the market, there hasn't been much pressure in offering discounts through value-based contracts to patients. Though, more discussions on this initiative are happening, Andy Killpack also of Magellan, said in the second-part of a two part AMCP annual meeting video series.
When asked for solutions in better managing expensive drug costs, Michelle Booth, Senior Director of Specialty Clinical Solutions of Magellan suggests a "mortgage-like" payment model that could help make these therapies, which are covered under medical benefits, more accessible and affordable.
"I know there isn't one great mortgage-like payment out there, but we need to realize this needs to be tweaked over time," she said of the suggestion.
Related: Adeno-Associated Virus Gene Therapies in the Pipeline, Barriers to Existing Drugs and Solutions
There would need to be more prevelance on these gene therapy conditons and more drugs to be approved that are expensive to see some action. If the affordability issue continues to be a problem, that's when pivoting toward new options will be necesneces.
Because there aren't many gene therapies out there just yet in the market, there hasn't been much pressure in offering discounts through value-based contracts to patients. Though, more discussions on this initiative are happening, Andy Killpack, director of Specialty Clinical Solutions of Magellan, said.
Emerging Therapies Committee at UC Davis Hits the Accelerator Not the Brake | AMCP 2024
April 18th 2024After the onboarding of cell and gene therapy bogged using normal pharmacy and therapeutics (P&T) committee procedures, UC Davis Health set up an emerging therapeutics committee to streamline and speed up the process of delivery expensive cell and gene therapies.
Read More
Potential Generics Could Lower Prices for Oncology, Cardiovascular Drugs | AMCP 2024
April 18th 2024Up to 50 generics could be approved this year, including Victoza to treat patients with diabetes. If generics of Victoza become available, this would the first GLP-1 to face generic competition.
Read More
Are Value-Based Contracts the Answer to Ultra-High-Priced Gene Therapies? | AMCP 2024
April 17th 2024Innovative contracts are becoming more common for gene therapies. They aim to balance a therapy’s cost-effectiveness and affordability, as well as address the uncertainty of long-term benefit.
Read More
